Navigation Links
High-Dose Flu Vaccine May Better Protect the Elderly: Study
Date:8/13/2014

By
HealthDay Reporter

WEDNESDAY, Aug. 13, 2014 (HealthDay News) -- The high-dose flu shot protects seniors better than the standard dose does, a new study finds.

About one in four cases of flu in older patients vaccinated with the standard dose could be prevented if the high-dose vaccine were used instead, the researchers reported.

"The study demonstrated a 24 percent reduction in influenza illness among the participants who received the high-dose vaccine compared to those who received the standard dose," said study co-author Dr. David Greenberg, vice president for scientific and medical affairs and chief medical officer for Sanofi Pasteur U.S., the maker of the Fluzone High-Dose vaccine and funder of the trial.

This protection is over and above the protection one gets from the standard flu shot, Greenberg noted.

He pointed out that the added protection is essential for older people. "People 65 and older account for about 60 percent of hospitalizations due to flu and about 90 percent of deaths that are flu-related," he said.

Older people tend to have weaker immune systems and don't respond as well to the standard flu shot, Greenberg explained. The high-dose vaccine was designed to address these weaknesses, he said.

Fluzone High-Dose vaccine is an inactivated influenza vaccine containing four times the vaccine found in the standard dose, Greenberg explained.

Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, said he recommends the high-dose vaccine for his older patients. "People 65 and older do not process vaccines as well as younger people," he explained.

"Protection from the flu vaccine is not 100 percent -- it's about 60 percent effective," Horovitz said. "But if you can increase it by 15 or 20 percent, that's something."

Dr. Ambreen Khalil, an infectious diseases specialist at Staten Island University Hospital in New York City, said she is also inclined to give the high-dose vaccine to her older patients.

"We did have a lot of vaccine failure this year. A lot of patients got sick even after taking the vaccine, so if we can do something better for these patients then I would consider doing that for my patients," Khalil said.

Fluzone High-Dose is approved for people 65 and older, but is not recommended for people who have had a severe reaction to the flu vaccine in the past, according to the U.S. Centers for Disease Control and Prevention.

The CDC does not specifically recommend Fluzone High-Dose for all seniors. Rather, the agency recommends "flu vaccination as the first and most important step in protecting against flu viruses."

The report was published Aug. 14 in the New England Journal of Medicine.

For the study, researchers randomly assigned nearly 32,000 men and women aged 65 and older to receive either the high-dose flu shot or a regular dose.

Greenberg and his colleagues found that people given the high-dose shot produced more antibodies against the flu than those given the standard dose.

Greenberg also noted that the high-dose vaccine may help prevent hospitalizations, pneumonia, heart and lung problems, doctor visits and medication use.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on the flu.

SOURCES: David Greenberg, M.D., vice president, scientific and medical affairs, and chief medical officer, Sanofi Pasteur U.S., Swiftwater, Penn.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; Ambreen Khalil, M.D., infectious diseases specialist, Staten Island University Hospital, New York City; Aug. 14, 2014, New England Journal of Medicine


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. High-dose fluticasone effective against eosinophilic esophagitis
2. Predicting outcome for high-dose IL-2 therapy in cancer patients
3. Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Associated Cancers by 62 Percent
4. High-Dose Statins Linked to Acute Kidney Damage
5. High-dose Vorinostat effective at treating relapsed lymphomas
6. Controlling spine metastases with tumor separation surgery and high-dose stereotactic radiosurgery
7. Microvax cancer vaccine first in human clinical trial in Singapore
8. HPV vaccine could close the gap on Indigenous health
9. MicroVAX Cancer Vaccine First in Human Clinical Trial in Singapore
10. Ebola Vaccine Trials Set to Begin in September
11. A vaccine alternative protects mice against malaria
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High-Dose Flu Vaccine May Better Protect the Elderly: Study 
(Date:4/21/2017)... Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at Palm ... , will be taking part in the 2017 London Marathon. Set to take place on ... of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, raising ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: